Drug Profile
Research programme: Clostridium difficile infection therapeutics - Arietis Corporation
Latest Information Update: 29 Jan 2018
Price :
$50
*
At a glance
- Originator Arietis Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Clostridium difficile infections
Most Recent Events
- 29 Jan 2018 Discontinued for Clostridium difficile infections in USA (unspecified route) (Arietis Corporation website, January 2018)
- 16 Jul 2016 No recent reports of development identified for research development in Clostridium difficile infections in USA
- 01 Oct 2012 Early research in Clostridium difficile infections in USA (unspecified route)